Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility

Lancet. 2003 Jan 11;361(9352):184. doi: 10.1016/s0140-6736(03)12225-8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Chelation Therapy / methods
  • Deferiprone
  • Deferoxamine / pharmacokinetics
  • Deferoxamine / therapeutic use*
  • Half-Life
  • Humans
  • Iron / metabolism
  • Iron Chelating Agents / pharmacokinetics
  • Iron Chelating Agents / therapeutic use*
  • Pyridones / pharmacokinetics
  • Pyridones / therapeutic use*
  • beta-Thalassemia / drug therapy*
  • beta-Thalassemia / metabolism

Substances

  • Iron Chelating Agents
  • Pyridones
  • Deferiprone
  • Iron
  • Deferoxamine